Sesquiterpene lactones (SLs) are plant-derived constituents that have been proved to have potential antitumour activity. However, the intracellular molecular targets of SLs and the underlying molecular mechanisms have not been well elucidated. Here, we report that F1012-2, a novel SL active fraction, isolated from Eupatorium lindleyanum DC., can significantly inhibit the growth of triple-negative breast cancer (TNBC) cells (MDA-MB-231 and MDA-MB-468) but has no obvious inhibitory effect on the growth of human mammary epithelial cells (MCF-10A). The related mechanisms on cell growth inhibition of F1012-2 were demonstrated by inducing apoptosis in a caspase-dependent manner through the intrinsic pathway and extrinsic pathway. F1012-2 could also activate autophagy in TNBC cells. Simultaneously, we found that F1012-2-induced apoptosis was enhanced by inhibition of autophagy. Furthermore, F1012-2 could induce cell cycle arrest at G2/M phase with decreasing expression of cyclin B1, cdc2, and upregulating p21, p-cdc2. Also, F1012-2 activated Akt and p38 signalling pathways. In vivo, F1012-2 exhibited a potential antitumour effect in MDA-MB-231 xenografts without apparent toxicity. Taken together, our results identified that F1012-2 inhibited cell growth via multiple signalling pathways in vitro and in vivo. These data suggest that F1012-2 may be a potential natural active fraction for the treatment of TNBC.
have a variety of biological activities in inhibiting proliferation, migration, invasion, and inducing apoptosis in different types of cancer cells, such as lung cancer, breast cancer, leukaemia, and colorectal cancer (Cotugno et al., 2012; Fang et al., 2010; Lee, Hwangbo, Lee, Seo, & Lee, 2010; Rasul et al., 2013) . However, the intracellular molecular targets of SLs have not been well elucidated, and continued work is needed to identify the mechanisms of SLs in cancer therapy.
Eupatorium lindleyanum DC. (Compositae), called "Ye-Ma-Zhui" by local residents, is a perennial herbaceous plant. F1012-2, a novel SL active fraction was isolated from the E. lindleyanum DC for the first time. In this study, we investigated the anticancer effect of F1012-2 by tracking activity on TNBC cells. The results show that anti-TNBC effect of F1012-2 is significant, but it has no obvious inhibitory effect on the growth of human normal mammary MCF-10A cells. Mechanistically, we demonstrate that inhibitory effect of F1012-2 is regulated by the induction of apoptosis and cell cycle arrest at the G2/M phase.
Furthermore, F1012-2 also induces autophagy, which resists the posttreatment apoptosis. Further study on mechanism shows that p38 and Akt signalling pathways are also involved in the process of inhibiting growth. Therefore, F1012-2 inhibits the growth of TNBC cells through multiple signalling pathways, which is expected to become a potential agent for the treatment of TNBC.
| MATERIALS AND METHODS

| Cell culture and reagents
MDA-MB-468 and MDA-MB-231 cells were purchased from the Cell Bank of the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco's modified Eagle's medium/F12 culture medium (Gibco, Gaithersburg, MD, USA), supplemented with 10% fetal bovine serum (Gibco, Gaithersburg, MD, USA). Human mammary epithelial MCF-10A cells (Chinese Academy of Sciences, Shanghai, China) were maintained in Dulbecco's modified Eagle's medium/F12 (Gibco) supplemented with hydrocortisone (0.5 μg/ml), insulin (10 μg/ml), endothelial cell growth supplements (20 ng/ml; Sigma-Aldrich, St. Louis, MO, USA) and 10% fetal bovine serum (Gibco). Cells were incubated with 5% CO 2 at 37°C in a humidified atmosphere.
F1012-2 was kindly provided by Dr. Bo Yang (Zhejiang Chinese
Medical University, Hangzhou, China). It is consisted of three compounds Eupalinolide G, Eupalinolide I, and Eupalinolide J. The three compounds' structures can be seen in the Supporting Information. They are different from Eupalinolide O (Yang, Zhao, Lou, & Zhao, 2016) , and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT), acridine orange (AO), 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylimidacarbocyanine iodide (JC-1), dimethyl sulfoxide, and 3-methyladenine (3-Ma) were purchased from Sigma-Aldrich. The pan caspase inhibitor Z-VAD-FMK was purchased from Selleckchem (Houston, TX, USA). Propidium iodide/RNase staining cell cycle kit and Annexin V-FITC/7AAD apoptosis kit were purchased from BD Pharmingen (San Diego, CA, USA). Antibodies against caspase-3 (#9662), cleaved caspase-3 (Asp175, #9664), cdc2 (#9116), phosphoAkt (Ser473, #4060), Akt (pan, #4691), phospho-cdc2 (Tyr15, #4539), poly ADP-ribose polymerase (PARP) (#9532), cyclin B1 (#12231), Bcl-2 (#2870), Bcl-xl (#2764), caspase-8 (#4790), caspase-9 (#9508), cleaved caspase-9 (#9501), β-tubulin (#2128), p-p38 (Thr180/Tyr182, #4511), Beclin-1 (#3738), p53 (#2527), p27 (#3686), LC3 (#3868), Bax (#2774), and horseradish peroxidase-conjugated secondary antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Bad (N-term, ab32445), p38 (ab32142), and p21 (ab18209) were purchased from Abcam (Cambridge, MA, USA). 
| Cell viability assay
| Evaluation of mitochondrial membrane potential (Δψ m )
TNBC cells (3 × 10 5 cells/well) were seeded in 6-well plates for 24 hr before the experiment. After treatment with 0, 2, 4, and 8 μg/ml F1012-2 for 24 hr, cells were harvested, washed twice with ice-cold PBS, and incubated with JC-1 (10 μg/ml) in the dark for 15 min at 37°C. Cells were washed three times with ice-cold PBS and analysed by flow cytometry using emission wavelengths of 590 and 529 nm. 3 | RESULTS
| Western blotting analysis
| F1012-2 inhibits the growth of TNBC cells
To evaluate the antiproliferative effect of F1012-2 on TNBC cells, we to F1012-2's (data not shown). However, the yield of F1012-2 is much higher than those of three compounds. So, F1012-2 is more worthy of being studied.
| F1012-2 induces cell cycle arrest at G2/M phase in TNBC cells
To investigate the mechanisms of the inhibitory effects of F1012-2 on the growth of TNBC cells, we first examined its effect on cell cycle progression by flow cytometry. As shown in Figure 2a Then the molecular mechanism of F1012-2's effects on cell cycle arrest was explored by western blotting. As shown in Figure 2c , after treatment with F1012-2, expression of cyclin B1, cdc2, and mutant p53 (mtp53) is downregulated, whereas expression of p21, p-cdc2 (Tyr15), and p27 is upregulated in a dose-dependent manner. These results suggest that cell cycle arrest at G2/M phase may be associated with anticancer effect of F1012-2 on TNBC cells.
| F1012-2 induces apoptosis in TNBC cells by activation of caspases
To further investigate whether the inhibitory effect of F1012-2 on the growth of TNBC cells was associated with the induction of apoptotic cell death, flow cytometry was used. As shown in Figure 3a ,b, the rates of F1012-2-elicited apoptosis cells were significantly increased in a dose-dependent manner in both cells. After treatment with 8 μg/ml F1012-2, the apoptotic rates of MDA-MB-468 and MDA-MB-231 cells were increased by 36.83 ± 1.05% and 37.74 ± 1.05%, respectively, compared with the vehicle control groups.
As is known to all, activation of caspases plays important roles in cancer cell death (Tiwari et al., 2015) . To confirm whether caspases are involved in F1012-2-induced apoptosis, we analysed the activation of caspases and the expression of PARP by western blotting. As shown in Figure 3c , F1012-2 treatment significantly downregulates protein levels of pro-caspase-3, pro-caspase-8, and
pro-caspase-9 and upregulates protein levels of cleaved caspase-3 and cleaved caspase-9. To further investigate enzymatic activation of caspase-3, we measured cleaved PARP (poly [ADP-ribosyl] polymerase), which is a substrate of caspase-3 and an enzyme to protect DNA (Lazebnik, Kaufmann, Desnoyers, Poirier, & Earnshaw, 1994) . The formation of fragment of PARP was found after treatment with F1012-2. These results demonstrate that F1012-2 induces apoptosis by activation of caspases, indicating that caspases activation may be the mechanism of regulating apoptotic activity of F1012-2 in TNBC cells.
| F1012-2 induces apoptosis in a caspasedependent manner
To investigate whether F1012-2-induced apoptosis was caspasedependent, the effect of caspase inhibitor Z-VAD-FMK on preventing F1012-2-induced cell death was examined. As shown in 
| F1012-2 induces mitochondrial dysfunction and regulates the expression of Bcl-2 family proteins
The most striking feature of early apoptosis is the change of mitochondrial membrane potential (ΔΨm; Singh, Sharma, & Katiyar, 2011) . The loss of ΔΨm is regarded as a hallmark of apoptosis that occurs prior to caspase activation (Orrenius, Gogvadze, & Zhivotovsky, 2007) . 
| F1012-2 induces autophagy in TNBC cells
To ascertain whether F1012-2 induces autophagy in TNBC cells, we examined the formation of autophagic vacuoles with AO staining. As shown in Figure 6a , F1012-2 treatment resulted in an increasing appearance of acid vesicular organelles in a dose-dependent manner.
To elucidate the molecular mechanisms, we examined the related proteins' level. The results showed that after treatment with 
| Autophagy inhibition enhances F1012-2-induced apoptosis in TNBC cells
Numerous studies have shown that autophagy has a dual role in tumourigenesis, either functioning as a tumour suppressor or maintaining cell survival under stress (Degenhardt et al., 2006; Gautam Das, 2012; Kondo, Kanzawa, Sawaya, & Kondo, 2005) . To investigate whether F1012-2-induced autophagy imparted a protective or detrimental effect, autophagy inhibitor 3-Ma was used. As shown in Figure 7a ,b, the cells exposed to both F1012-2 and 3-Ma exhibited a higher rate of apoptosis compared with those treated with F1012-2 alone. The combination of 3-Ma and F1012-2 increased the apoptotic cells by 18.83 ± 1.59% (MDA-MB-468) and 22.51 ± 3.02% (MDA-MB-231), respectively. Moreover, western blotting analysis showed that expressions of cleaved caspase-3 and PARP were upregulated after autophagy inhibition (Figure 7c ). The data above suggest that F1012-2-induced autophagy imparts a protective effect.
| F1012-2 regulates Akt and p38 MAPK signalling pathways in TNBC cells
The MAPKs-and Akt-mediated signalling pathways have been shown to be a critical regulator of cell growth, differentiation, apoptosis, survival, and autophagy (Atmaca, Ozkan, & Zora, 2017; Khavari & Rinn, 2007 ; D. Wang et al., 2014) . To further identify whether Akt and p38 signalling pathways are involved in mechanisms underlying F1012-2-mediated growth inhibition in TNBC cells, the related proteins were detected. As shown in Figure 8 , expression of phosphorylated p38 
| F1012-2 inhibits breast cancer growth in vivo
To evaluate the effect of F1012-2 in vivo, we examined the effect of F1012-2 on tumour growth in a well-established xenograft model.
The results showed that the tumour volume and weight were decreased significantly in the F1012-2-treated groups compared with those of the control group (Figure 9a-c) . Moreover, there was no difference of body weight in all groups, meaning that F1012-2 was apparently nontoxic to the animals (Figure 9d ). To characterize the molecular mechanisms in vivo, TUNEL assay was used to evaluate the apoptotic cells in the tumour tissue. The levels of apoptosis were significantly increased in the F1012-2-treated group compared with the control group (Figure 9e ). These data demonstrate that F1012-2 inhibits the growth of MDA-MB-231 human breast cancer xenograft in vivo. 
| DISCUSSION
Numerous studies have reported that some SL compounds, such as thapsigargin, parthenolide, and isoalentolactone, have been extensively explored in cancer research (Christensen et al., 2009; Taleghani, Nasseri, & Iranshahi, 2017; J. Wang et al., 2016) .
Therefore, searching for the antitumour targets of SLs is crucial for treatment of cancer and development of natural drugs. F1012-2, a novel SL active fraction, was extracted from the E. lindleyanum DC.
In this study, F1012-2 is demonstrated to have a strong inhibitory effect on the growth of TNBC cells in time-and dose-dependent manner. And it has low toxicity on human mammary epithelial MCF-10A cells (Figure 1 ). Hence, we further try to investigate the underlying mechanisms of TNBC cell death induced by F1012-2 in more detail.
In our study, we found that F1012-2-induced TNBC cell death through cell cycle arrest at the G2/M phase (Figure 2 ), inducing cell apoptosis by activation of caspases ( Figure 3 ) and disruption of ΔΨm ( Figure 5) . Notably, the effect of F1012-2 on induction of apoptosis was in a caspase-dependent manner (Figure 4) . Moreover, F1012-2 could trigger autophagy (Figure 6 ), and autophagy inhibited the percentage of apoptosis in both TNBC cells (Figure 7) . Furthermore, F1012-2 can suppress phosphorylation of Akt and correlates with activation of p38 phosphorylation (Figure 8) . The above data show that Wang, Wang, & Soong, 2000) . Various studies have shown that p53 can activate expression of cyclin-dependent kinase inhibitors (e.g., p21 and p27), then inhibits cyclin-dependent kinases, and leads to cell cycle arrest (Coqueret, 2003; Oren, 2003) .
p53 regulates G2/M transition through induction of p21 and p27, downregulating the intracellular level of cyclin B1 (Bunz et al., 1998; Innocente, Cogswell, & Lee, 1999) . In our study, F1012-2 significantly upregulated the expression of p21, p27, and p-cdc2 (Tyr15) together with downregulation of mutant p53, cyclin B1, and cdc2 (Figure 2 ). Taken together, F1012-2 induces the cell Programmed cell death (PCD) is a process that is integral not only to normal physiological development and tissue homeostasis but also as a defence mechanism against various forms of human disease (Miura, 2011) . Apoptosis (Type I PCD) induced by some anticancer agents constitutes one aspect of treatment effects. Principally, apoptosis is thought to occur through two main pathways: the intrinsic pathway (death signal arises from the inside of the cell) and the extrinsic pathway (activation of cell surface receptors by an extracellular death signal)-both of which eventually converge and activate effector caspases (Degterev, Boyce, & Yuan, 2003) . Consistent with the above notion, F1012-2 significantly downregulated expression of pro-caspase-3, pro-caspase-9, and pro-caspase-8 and upregulated protein levels of cleaved caspase-3 and caspase-9 and PARP (Figure 3) . These results demonstrated that F1012-2 induced apoptosis by triggering the intrinsic and extrinsic apoptotic pathways. Interestingly, F1012-2 can induce caspasedependent apoptosis as evidenced by the reversal effects of pancaspase inhibitor Z-VAD-FMK (Figure 4) .
Mitochondria represent the central checkpoint in propagating apoptotic signalling pathways (Charlot, Prétet, Haughey, & Mougin, 2004) . Upon exposure to apoptotic stimuli, it can cause loss of ΔΨm and activate caspase cascade eventually leading to cell death (Haga, Fujita, & Tsuruo, 2003; Sivalingam, Paramasivan, Weng, & Vijaya Padma, 2017) . Bcl-2 family members are major regulators by mitochondria. They can change their conformations to form mitochondrial permeability transition pores in the outer mitochondrial membrane (Borkan, 2016) . In accordance with the previous theory, after Not surprisingly, cell death is a complex and well-controlled process. Apoptosis (Type I PCD) has been extensively studied, and its contribution to the pathogenesis of disease has been well documented.
However, apoptosis does not function alone in determining the fate of a cell. More recently, autophagy (Type II PCD) has been shown to engage in complex interplay with apoptosis. It can de novo form membrane enclosed vesicles engulf and consume cellular components (Booth, Tavallai, Hamed, Cruickshanks, & Dent, 2014) . Once autophagy is initiated, LC3-I is transformed into LC3-II and translocates to the surface of autophagosomes from the cytoplasm. LC3-II is an autophagy-related, ubiquitin-like modifier, which is regarded as an autophagosomal marker in mammals cells (Tanida, Ueno, & Kominami, 2004) . Consistently, the level of Beclin-1, a critical component for autophagosome initiation, significantly upregulated with autophagy (Kang, Zeh, Lotze, & Tang, 2011) . When autophagy is blocked, p62 as the ligand of LC3 is upregulated in the cytoplasm (Lippai & Low, 2014) . Autophagy is an important type of nonapoptotic cell death and implicated in cancer treatment. It remains controversial whether therapy-induced autophagy in cancer cells is a self-defence mechanism to maintain cell survival or a nonapoptotic form of PCD. Here, we found that F1012-2 induced accumulation of AO fluorescence. And it upregulated expressions of LC3-II and Beclin-1 and downregulated expression of p62. These results suggest that F1012-2 can induce autophagy. As expected, the upregulation of LC3-II induced by F1012-2 could be prevented by treatment of autophagy inhibitor 3-Ma. However, after pretreatment of 3-Ma, the rate of apoptosis in F1012-2-treated cells was significantly increased. Thus, it is clear that the autophagy induced by F1012-2 can exert cyto-protective effects on TNBC cells.
A growing amount of evidences demonstrate that the p38 and Akt signalling pathways participate in the regulation of cell proliferation, differentiation, and death by blocking cell cycle at G2/M phase and regulating the expression of Bcl-2 family proteins Porta, Paglino, & Mosca, 2014; Srinivas et al., 2016) . The p38 and Akt signalling pathways have recently been connected to autophagy (Nagappan et al., 2017; Pan et al., 2015) . In our study, treatment with F1012-2-induced apoptosis and autophagy, these results showed that F1012-2 could significantly suppress Akt signalling pathway and activate p38 signalling pathway in TNBC cells. These data suggest that F1012-2 inhibits cell growth via Akt suppression and p38 MAPK activation in the treatment of TNBC cells.
| CONCLUSION
In conclusion, our findings, from both in vitro and in vivo data, demonstrate for the first time that F1012-2 can inhibit cellular growth and tumourigenesis of TNBC with no obvious toxicity on human mammary epithelial cells and body weight of nude mice. Our data clearly provided that multiple signalling pathways might be involved in F1012-2-induced cell death in the treatment of TNBC cells (Figure 10 ). We propose that F1012-2 is an efficient promising agent for anti-TNBC prevention and therapy and that a better understanding of the underlying molecular mechanisms could contribute to anti-TNBC therapy in the near future.
